ruxolitinib plus venetoclax for t-pll: rationale and findings
Published 3 years ago • 591 plays • Length 1:26Download video MP4
Download video MP3
Similar videos
-
2:58
itacitinib plus alemtuzumab for patients with t-pll
-
1:21
ruxolitinib plus venetoclax in heavily pretreated patients with r/r aml
-
2:40
venetoclax and ruxolitinib treatment strategies for myeloma
-
1:38
pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
-
3:16
ponatinib plus venetoclax for r/r ph all
-
1:56
ibrutinib plus venetoclax for first-line treatment of cll: 4-year follow-up data
-
1:02
ponatinib venetoclax for the treatment of r/r ph all
-
1:59
treating r/r cll: the value of btkis and venetoclax
-
5:34
venetoclax added to ibrutinib in patients with cll with molecular resistance to btki treatment
-
2:49
results from the phase iii echo trial of acalabrutinib plus br in mcl
-
1:46
ruxolitinib in 2024 and beyond: the good, the suboptimal, and the failure
-
0:51
phase i study of copanlisib plus venetoclax in r/r dlbcl
-
1:25
updates on ponatinib plus venetoclax for r/r ph all
-
3:42
acalabrutinib plus venetoclax and rituximab in mcl & the importance of chemotherapy-free regimens
-
1:23
the current treatment landscape for patients with t-cell prolymphocytic leukemia
-
1:36
improve study update: safety and efficacy of venetoclax retreatment in r/r cll
-
3:36
obinutuzumab plus venetoclax in early r/r dlbcl
-
3:09
bleximenib combined with venetoclax and azacitidine in r/r aml with kmt2a or npm1 alterations
-
3:15
ponatinib, venetoclax and dex for r/r ph all
-
1:17
exploratory analysis of the clarity study: ibrutinib plus venetoclax in patients with r/r cll
-
1:35
pirtobrutinib in r/r fl: results from the bruin study
-
2:17
epcore cll-1: epcoritamab in patients with r/r cll & richter's transformation